Metformin ER

Phase 3Small molecule

Teva

Metformin ER is one of 72 small molecule programs targeting Polycystic Ovary Syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Polycystic Ovary SyndromeActive, not recruiting

Intermittent ClaudicationRecruiting

ProspectiveWithdrawn

Polycystic Ovary SyndromePreclinical

Active, not recruiting

Intermittent ClaudicationPhase 3

Recruiting

ProspectivePreclinical

Withdrawn

Competition

Competitive Landscape

71 competitors in Polycystic Ovary Syndrome

#DrugCompanyPhaseTrials

Glucophage

EMD Serono

Approved

56 2

Actos

Takeda

Approved

6 3

Ozempic

Novo Nordisk

Approved

2 4

Avandia

Jazz Pharmaceuticals

Approved

2 5

Daliresp

AstraZeneca

Approved

1 6

Onglyza

Calciferol

Evista

Glucophage

3 10

Gynorest

SSolvay Pharmaceuticals

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 3Recruiting

Preeclampsia

NCT06033131

Q1 2031

Phase 3Recruiting

Intermittent Claudication

NCT05132439

Clinical

Trials by Indication[1]

Metformin5 trials

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (5mg/1000mg) Extended Release in Healthy Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02084082·68 enrolled

Metformin ER 750 mg Tablets, Fasting

Completed· Teva logo

Teva·Phase 1·NCT00834743·32 enrolled

Metformin ER 750 mg Tablets, Fed

Completed· Teva logo

Teva·Phase 1·NCT00834613·32 enrolled

Show 2 more trials

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02121509·74 enrolled

Tolerability and Pharmacokinetics of Metformin and Metformin Extended Release (ER)

Completed·LLaboratorios Silanes S.A. de C.V.·Phase 1·NCT00941239·24 enrolled

Polycystic Ovary Syndrome2 trials

Polycystic Ovary Syndrome Genetics and Treatment Response

Unknown status·MMassachusetts General Hospital·N/A·NCT01389778·200 enrolled

Metformin Treatment in Polycystic Ovary Syndrome (PCOS)

Unknown status·MMassachusetts General Hospital·N/A·NCT02198417·20 enrolled

Prospective1 trial

Prospective Trial of Metformin - Chemoprevention Role

Withdrawn·MM.D. Anderson Cancer Center·N/A·NCT01550900

Dapagliflozin1 trial

An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed Conditions

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02722239·40 enrolled

Pilot Study1 trial

An Open-Labeled Pilot Study of Biomarker Response Following Short-Term Exposure to Metformin

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT01816659·3 enrolled

3 more indications

Intermittent Claudication1 trial

MetfOrmin BenefIts Lower Extremities With Intermittent Claudication

Recruiting·VVA Office of Research and Development·Phase 3·NCT05132439·200 enrolled

Surgical1 trial

REMAP Trial for Optimizing Surgical Outcomes at UPMC

Terminated·MMatthew Neal MD·Phase 3·NCT03861767·302 enrolled

Preeclampsia1 trial

Preeclampsia Intervention 4 - A Triple Blind Phase III Randomised Controlled Trial Assessing Metformin to Prolong Gestation in Preterm Preeclampsia

Recruiting·LLina Bergman·Phase 3·NCT06033131·294 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Metformin ER. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Metformin ER compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Metformin ER. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Teva company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Teva

Metformin ER

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Q1 2031

Trials by Indication[1]

Metformin5 trials

Polycystic Ovary Syndrome2 trials

Prospective1 trial

Dapagliflozin1 trial

Pilot Study1 trial

Intermittent Claudication1 trial

Surgical1 trial

Preeclampsia1 trial

References

Drug Info

Quick Facts

Related News